Selective serotonin reuptake inhibitors may help men with premature ejaculation, but with risk of adverse events

Selective serotonin reuptake inhibitors may help men with premature ejaculation, but with risk of adverse events

Vanessa Jordan
PEARLS No.
675
Clinical question

Are selective serotonin reuptake inhibitors an effective treatment for adult men with premature ejaculation?

Bottom line

Compared with placebo, the admin­istration of SSRIs for premature ejaculation may improve perception of change with treatment and satisfaction with intercourse. SSRIs may also im­prove perceived control over ejaculation and reduce both distress about premature ejaculation and relationship difficulties. These potential benefits need to be weighed up against the possible increase in adverse events with SSRIs.

Caveat

The review did not include any active com­parators and, therefore, is unable to address how these drugs compare with other management approaches, such as topical anaesthetics, tramadol or alpha-1 adrenoreceptor antagonists, which are rec­ommended as treatment alternatives.

A specific concern in the use of SSRIs for depression is the potential risk of promoting suicidal ideation, although this remains an issue of controversy. The reported adverse events and study withdrawals of the included studies did not provide a signal for this outcome, but the overall number of participants and the relatively short follow‐up of these studies limit the ability to identify infrequent outcomes that might be associated with long‐term use.

Context

Premature ejaculation is a common prob­lem among men that occurs when ejaculation hap­pens sooner than a man or his partner would like during sex; it may cause unhappiness and relation­ship problems. SSRIs, which are most commonly used as antidepressants, are being used to treat this condition.

Cochrane Systematic Review

Sathianathen NJ, et al. Selective serotonin re‐uptake inhibitors for premature ejaculation in adult men. Cochrane Da­tabase Syst Rev 2021;3:CD012799. This review contains 31 trials with a total of 8254 participants.